Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 24.24
-1.28 (-5.02%)
Aug 21, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,532 | 7,963 | 8,811 | 12,808 | 21,257 | 42,401 | |
Market Cap Growth | 23.61% | -9.63% | -31.21% | -39.74% | -49.87% | - |
Enterprise Value | 10,592 | 6,100 | 6,995 | 10,670 | 18,877 | 41,383 |
Last Close Price | 24.24 | 14.99 | 16.49 | 23.66 | 37.79 | 75.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 35.77 | 62.51 |
Forward PE | 117.44 | 74.61 | 43.68 | 48.03 | 23.21 | 43.93 |
PS Ratio | 8.87 | 5.78 | 6.40 | 9.96 | 5.96 | 22.69 |
PB Ratio | 3.30 | 2.10 | 2.23 | 3.18 | 4.61 | 10.27 |
P/TBV Ratio | 3.49 | 2.23 | 2.37 | 3.37 | 4.80 | 10.32 |
P/FCF Ratio | 74.66 | 42.86 | - | - | - | 119.49 |
P/OCF Ratio | 59.77 | 34.15 | - | 83.72 | 28.91 | 68.74 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.49 | 4.43 | 5.08 | 8.30 | 5.29 | 22.15 |
EV/EBITDA Ratio | - | - | - | - | 20.66 | 54.37 |
EV/EBIT Ratio | - | - | - | - | 22.20 | 56.70 |
EV/FCF Ratio | 63.10 | 32.84 | - | - | - | 116.63 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.27 | 0.22 | 0.19 | 0.32 | 0.10 | 0.02 |
Debt / EBITDA Ratio | 32.12 | 36.61 | 18.95 | - | 0.47 | 0.12 |
Debt / FCF Ratio | 6.00 | 4.54 | - | - | - | 0.26 |
Net Debt / Equity Ratio | -0.51 | -0.53 | -0.48 | -0.54 | -0.61 | -0.81 |
Net Debt / EBITDA Ratio | 169.62 | 101.87 | 656.28 | 12.62 | -3.07 | -4.42 |
Net Debt / FCF Ratio | -11.51 | -10.83 | 22.52 | 27.45 | 12.32 | -9.48 |
Asset Turnover | 0.27 | 0.27 | 0.26 | 0.22 | 0.67 | 0.60 |
Inventory Turnover | 1.28 | 1.30 | 1.24 | 1.45 | 4.59 | 2.08 |
Quick Ratio | 3.04 | 3.19 | 3.50 | 2.53 | 3.56 | 9.76 |
Current Ratio | 3.39 | 3.56 | 3.95 | 2.78 | 3.96 | 10.46 |
Return on Equity (ROE) | -0.58% | -0.58% | -0.49% | -1.69% | 13.58% | 24.85% |
Return on Assets (ROA) | -1.19% | -1.39% | -1.31% | -2.89% | 10.02% | 14.67% |
Return on Invested Capital (ROIC) | -5.43% | -5.85% | -5.83% | -14.91% | 64.41% | 119.81% |
Return on Capital Employed (ROCE) | -2.50% | -2.80% | -2.70% | -6.40% | 17.50% | 17.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.11% | -0.21% | -0.21% | -0.55% | 2.80% | 1.60% |
FCF Yield | 1.34% | 2.33% | -0.96% | -0.62% | -1.07% | 0.84% |
Dividend Yield | 1.66% | 2.57% | 0.84% | 0.33% | 2.54% | 0.40% |
Payout Ratio | - | - | - | - | 22.25% | 0.66% |
Buyback Yield / Dilution | -28.92% | -14.77% | 8.27% | 1.18% | -9.95% | -1.96% |
Total Shareholder Return | -27.25% | -12.21% | 9.11% | 1.51% | -7.41% | -1.56% |